Sekisui Medical and Rayal Group Announce Strategic Partnership to Advance IVD Collaboration in China

On July 16, 2024, the signing ceremony for the strategic cooperation agreement between SEKISUI MEDICAL TECHNOLOGY(CHINA)LTD. (hereinafter referred to as “Sekisui Medical”), a nationally renowned IVD enterprise in China, and Shenzhen Realife Group Co., Ltd. (hereinafter referred to as “Realife”), was held as scheduled in Shenzhen. Mr. Gao Yeqiang, General Manager of Sekisui Medical, and Mr. Su Shaobo, Chairman of Realife, attended the ceremony and signed the agreement on behalf of their respective companies.

Ruiyali and SEKISUI MEDICAL TECHNOLOGY(CHINA)LTD. have established a strategic partnership in areas such as collaborative R&D (including biobank services), joint laboratories, and comprehensive supply chain solutions, thereby supporting SEKISUI’s localization strategy in the Chinese market. This signing aims to further strengthen bilateral cooperation through strategic collaboration, demonstrating tangible commitment to fostering the robust development of the healthcare industry. Ruiyali is dedicated to addressing pain points for downstream manufacturers by leveraging its biobank resources through collaborative R&D and joint laboratories, helping them overcome challenges in research, development, and production. The company strives to become a sustainable, stable, and high-quality supplier of core raw materials.

General Manager Gao Ye Qiang stated, “We are delighted to have reached a strategic partnership with Rialy in areas such as collaborative R&D, joint laboratories, and comprehensive supply chain solutions. We look forward to a successful collaboration between both parties.”

Chairman Su Shaobo stated, “We are delighted to become a strategic partner of SEKISUI MEDICAL TECHNOLOGY(CHINA)LTD. We hope that our future cooperation will be even closer, jointly promoting the development and advancement of China’s healthcare industry.”

SEKISUI MEDICAL TECHNOLOGY (CHINA) LTD. is a wholly Japanese-owned subsidiary of Sekisui Chemical Co., Ltd., with its operations managed and guided by Sekisui Medical Co., Ltd. Its business scope covers the research and development, import, and sales of in vitro diagnostic (IVD) reagents; the production and sales of single-use vacuum blood collection tubes; as well as the development and introduction of medical device products, sales of research reagents, and technical consulting services. To date, SEKISUI MEDICAL TECHNOLOGY (CHINA) LTD. has obtained over 100 registration certificates for various IVD reagents, spanning numerous fields such as clinical laboratory testing, coagulation, and therapeutic drug monitoring, while continuously introducing new products. The manufacturing facility for single-use vacuum blood collection tubes has achieved ISO 9001 and ISO 13485 medical device quality management system certifications, CE product certification, and IVD certification. Its products are bestsellers across China and are also exported to Japan.

Shenzhen Realight Group Co., Ltd. was founded by a technical team led by Dr. Su Shaobo from the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. As an innovative technology platform company, it integrates extensive CXO services, IVD raw material supply, comprehensive quality control solutions, scientific research technical services, and high-end medical translation services. With access to a biobank resource of 3 million samples, the company possesses mature expertise in the import and export of biological products, raw material R&D, and production translation, with its business operations spanning the globe.